Close mobile menu×
Close mobile menu

Christopher B. Anderson, MD

Expertise in: 
Urology, Urologic Oncology, Testicular Cancer, Prostate Cancer, Kidney & Adrenal Cancer, Bladder Cancer
Accepting New Patients
Profile Headshot

Appointments

Book Online

Participating DocASAP doctors have online booking available without the need for a myColumbiaDoctors account.

Phone Appointments

New and Existing Patients: 
(212) 305-0114

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Clinical Expertise

  • Urologic Oncology
  • Testicular Cancer
  • Prostate Cancer
  • Kidney & Adrenal Cancer
  • Bladder Cancer
  • Urology
  • Robotic Partial Nephrectomy
  • Retroperitoneal Lymph Node Dissection
  • Robotic Surgery
  • Cystectomy
  • Kidney Cancer
  • Robotic Prostatectomy
  • Laparoscopic Nephrectomy
  • Nephrectomy
  • Cystoscopy
  • Neobladder
  • Partial Nephrectomy

Education & Training

  • MD, Northwestern University - Feinberg School of Medicine
  • Residency: Vanderbilt University Medical Center
  • Fellowship: Memorial Sloan Kettering Cancer Center

Honors & Awards

Super Doctors, Top New York Physicians Rising Stars Edition 2019

Super Doctors, Top New York Physicians Rising Stars Edition 2018

Super Doctors, Top New York Physicians Rising Stars Edition 2017

About Christopher Anderson

Book Appointment

Christopher B. Anderson, MD, Assistant Professor of Urology at CUMC, joined the Department of Urology in September 2015. He specializes in cancers of the bladder, prostate, kidney, testis and penis and performs both open and robotic surgeries. Dr. Anderson completed his medical degree from Northwestern University, completed his urology residency at Vanderbilt University, and then spent two years at Memorial Sloan Kettering Cancer Center as a fellow in urologic oncology. Following his residency, Dr. Anderson completed a urologic oncology fellowship at Memorial Sloan Kettering Cancer Center and obtained a Master of Public Health degree from Harvard University.

Dr. Anderson's research interests include factors that influence the quality of surgery, access to care for patients with bladder cancer, outcomes after robotic prostatectomy, and active surveillance strategies for men with prostate cancer. Dr. Anderson has published several peer-reviewed articles and was recognized as "Best Reviewer" in 2014 by The Journal of Urology and in 2016 by Cancer.

Dr. Anderson has clinical expertise in robotic prostatectomy for the treatment of prostate cancer, radical cystectomy with orthotopic neobladder for patients with bladder cancer, and partial nephrectomy for the treatment of kidney tumors. He also specializes in the multidisciplinary management of men with testicular cancer, including the use of primary and post-chemotherapy retroperitoneal lymph node dissection. He is currently the site leader for several clinical trials investigating the use of immunotherapy in patients with invasive and non-invasive bladder cancer. 

Academic Titles

  • Assistant Professor of Urology at CUMC

Committee/Societies/Council Memberships

Member, American Urological Association

Member, Society of Urologic Oncology

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

For billing questions, please call (212) 304-7956.

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • MVP Health Care-Hudson Health Plan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

TRICARE

  • TRICARE

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-0114
Fax:
(212) 305-0129
Primary
2
19 Bradhurst Avenue
Hawthorne, New York 10532
Phone:
(914) 750-4640

Research

Clinical Trials

Phase 1/2 Study of Modern Immunotherapy in BCG-relapsing Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Randomized Phase II Study of Neoadjuvant Nivolumab with and without Urelumab in Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

Grants

RANDOMIZED PHASE II STUDY OF NEOADJUVANT NIVOLUMAB WITH AND WITHOUT URELUMAB IN PATIENTS WITH CISPLATIN-INELIGIBLE MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER (P&S Industry Clinical Trial)

May 10 2019 - May 10 2024

PHASE 1/2 STUDY OF MODERN IMMUNOTHERAPY IN BCG-RELAPSING UROTHELIAL CARCINOMA OF THE BLADDER ? (ADAPT-BLADDER) HCRN/SUO-CTC GU16-243 (P&S Industry Clinical Trial)

May 6 2019 - May 6 2024

Selected Publications

Peer reviewed articles

Anderson CB, Lipsky M, Nandula SV, Freeman CE, Matthews T, Walsh CE, Li G, Szabolcs M, Mansukhani MM, McKiernan JM, Murty VV. Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes, Chromosomes and Cancer, 2019: 1-7.

Meng X, Chao B, Vijay V, Silver H, Margolin EJ, Balar A, Taneja SS, Shah O, Bjurlin MA, Anderson CB, Huang WC. High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma. Urology, 2019.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.  ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol, 2019 Jan;37(1):51-60

Gonzalez AN, Lipsky MJ, Li G, Rutman MP, Cooper KL, Weiner DM, Badalato G, Decastro GJ, Wenske S, McKiernan JM, Anderson, CB. The prevalence of bladder cancer during cystoscopy for asymptomatic microscopic hematuria. Urology, 2019 Apr; 126: 34-38.

Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. Urol Oncol, 2019; 37(6): 353.e17-353.e24.

Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, Decastro GJ, McKiernan JM, Anderson CB. Conservative management following clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study. J Urol, 2018; 200(5): 1005-1013.

Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, DeCastro G, Anderson C, Drake C, Benson M, McKiernan J.  Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology, 2018 Jan;111:116-121

Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vija V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB. Discordance between ureteroscopic biopsy and final pathology for upper tract urothelial carcinoma. J Urol, 2018; 199(6): 1440-1445.

Weingart SN, Atoria CL, Pfister D, Classen D, Killen A, Fortier E, Epstein AS, Anderson C, Lipitz-Snyderman A.  Risk Factors for Adverse Events in Patients With Breast, Colorectal, and Lung Cancer. J Patient Saf 2018 Feb 6; PMCID: PMC6078829

Lee Sh, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, Bergren SK, Pietzak EJ, Anderson CB, Benson MC, Coleman JA, Taylor BS, Abate-Shen C, McKiernan JM, Al-Ahmadie H, Solid DB, Shen MM. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell, 2018; 173(2): 515-528.  

Moran GW, Li G, Robins DJ, Matulay JT, McKiernan JM, Anderson CB. Systemic review and meta-analysis of the efficacy of chemotherapy with transurethral resection of bladder tumors as definitive therapy for muscle invasive bladder cancer. Bladder Cancer, 2017; 3(4): 245-258.

Sui W, Lim EA, Decastro GJ, McKiernan JM, Anderson CB. Use of adjuvant chemotherapy in patients with advanced bladder cancer after neoadjuvant chemotherapy. Bladder Cancer, 2017; 3(3): 181-189.

Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, Decastro GJ, McKiernan JM. Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Guerin therapy. Urology, 2017; 103: 149-153.

Lipitz-Snyderman A, Pfister D, Classen D, Atoria CL, Killen A, Epstein A, Anderson C, Fortier E, Weingart SN. Preventable and mitigable adverse events in cancer care: measuring risk and harm across the continuum. Cancer, 2017.

Lipitz-Snyderman A, Classen D, Pfister D, Killen A, Atoria CL, Fortier E, Epstein A, Anderson C, Weingart SN. Perforance of a trigger tool for identifying adverse events in oncology. J Oncol Pract, 2017; 13(3): 223-230.

Anderson CB, Gennarelli R, Herr HW, Elkin EB. Regionalization of radical cystectomy in the United States. Urol Oncol; 35(8); 528. 2017.

Onyeji IC, Sui W, Pagano MJ, Weinberg AC, James MB, Theofanides MC, Stember DS, Anderson CB, Stahl PJ. Impact of surgeon case volume on reoperation rates after inflatable penile prosthesis surgery. J Urol, 2017; 197(1): 223-229.

Sui W, RoyChoudry A, Wenske S, Decastro GJ, McKiernan JM, Anderson CB. Outcomes and prognostic factors of primary urethral cancer. Urology, 2017.

Sui W, Onyeji IC, James MB, Stahl PJ, RoyChoudhury A, Anderson CB. Risk factors for priapism readmission. J Sex Med, 2016; 13(10): 1555-61.

Lipitz-Snyderman A, Sima CS, Atoria CL, Elkin EB, Anderson CB, Blinder V, Tsai CJ, Panageas KS, Bach PB. Physician-driven variation in nonrecommended services among older adults diagnosed with cancer. JAMA Intern Med, 2016; 176(10): 1541-1548.

Anderson CB, Weber R, Patel D, Lowrance W, Mellis A, Cookson M, Lang M, Barocas D, Chang S, Newberger E, Montgomery JS, Weizer AZ, Lee CT, Kava BR, Jackson M, Meraney A, Sjoberg D, Bochner B, Dalbagni G, Donat M, Herr H. A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor. J Urol, 2016; 196(4): 1014-20

Anderson CB, Atoria CL, Touijer K, Ehdaie B, Elkin EB. Surgeon adoption of minimally invasive radical prostatectomy. Urol Pract 2016; 3(6): 505-510

Anderson CB, Rapkin B, Reaves BC, Sun AJ, Morganstern B, Donat M, Herr HW, Laudone VP, Bochner BB. Idiographic quality of life assessment before radical cystectomy. Psycho-Oncology, 2015. Nov 30.

Lipitz-Snyderman A, Weingart SN, Anderson C, Epstein A, Killen A, Classen D, Sima CS, Fortier E, Atoria CL, Pfister D. Detecting potentially avoidable harm in oncology using patient medical records. J Oncol Pract 2016; 12 (2): 178-179.

Anderson CB, Sternberg IA, Karen-Paz G, Kim PH, Sjoberg D, Vargas HA, Touijer K, Eastham JA, Ehdaie B. Age is associated with upgrading at confirmatory biopsy among men with prostate cancer treated with active surveillance. J Urol 2015; 194 (6): 1607-11.

Anderson CB, Tin AL, Sjoberg DD, Mulhall JP, Sandhu J, Touijer K, Laudone VP, Eastham JA, Scardino PT, Ehdaie B. Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols. BJU Int 2016; 117(6B): E46-51.

Anderson CB, Elkin EB, Atoria CL, Eastham JA, Scardino PT, Touijer T. The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices. Prostate Cancer Prostatic Diseases 2015; 18(1): 75-80.

Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, Penson DF, Smith JA Jr., May AT, Anderson CB, You C, Lee H, Barocas DA. Impact of complications and hospital-free days following radical cystectomy on health-related quality of life at one year. J Urol. 2014; 192(5): 1360-4.

Anderson CB, Alvarez J, Koyama T, Penson DF, Barocas DA. The impact of gender on utilization of pelvic lymphadenectomy at the time of radical cystectomy. Urology Practice 2014; 1(3): 146-150.

Barocas DA, Alvarez J, Koyama T, Anderson CB, Gray DT, Fowke JH, You C, Chang SS, Cookson MS, Smith JA Jr., Penson DF. Racial variation in the quality of surgical care for bladder cancer. Cancer 2014; 120(7): 1018-25.

Sawyer MD, Anderson CB, Viprakasit DP, Dietrich MS, Herrell SD, Miller NL. An individualized weight-based goal urine volume model significantly improves expected calcium concentrations relative to a 2-L goal urine volume. Urolithiasis 2013; 41(5): 403-9.

Anderson CB, Ni S, Makarov DV, Penson DF, Barocas DA. Centralization of Radical Prostatectomy in the United States. J Urol 2013; 189(2): 500-506.

Anderson CB, Kappa S, Moore D, Barocas DA, Morgan TM, Smith JS, Cookson MS, Chang SS. Predictors of Ureteroenteric Anastamotic Strictures after Radical Cystectomy: Does Approach Matter? J Urol 2013; 189(2): 541-547.

Anderson CB, Kafuman MR, Dietrich MS, Barocas DA, Chang SS, Cookson MS, Smith JA, Clark PE, Herrell SD. Recovery of urinary function following radical prostatectomy: identification of trajectory cluster groups. J Urol. 2012; 187(4): 1346-1351.

Anderson CB, Cookson MS, Chang SS, Clark PE, Smith JA, Kaufman MR. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012; 188(1): 200-204.

Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MC, Penson DF. Psychometric characteristics of a condition-specific health-related quality of life survey: the FACT-Vanderbilt cystectomy index. Urology 2012; 80(1): 77-83.

Anderson CB, Pyle AL, Woodworth A, Cookson MS, Smith JA, Barocas DA. Spurious elevations in prostate-specific antigen after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2011; 15(2): 182-188.

Anderson CB, Tanaka ST, Pope JC IV, Adams MC, Brock JW III, Thomas JC. Acute pain crisis as a presenting symptom of primary megaureter in children. J Pediatric Urol, 2011; 8(3): 254-257.

Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, Cookson ME, Smith JA Jr., Chang SS. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011; 78(1): 99-104.

Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA Jr., Clark PE. Preoperative Nutritional Status is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. Eur Urol 2011; 59: 923-928.

Anderson CB, Helfand BT, McVary KT. Holmium laser prostate resection for patients presenting with acute urinary retention. BJU Int. 2008. Dec; 102(11): 1623-8.

Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT. Postoperative PSA and PSA velocity identify presence of prostate cancer following various surgical interventions for benign prostatic hyperplasia. J Urol. 2009. 74: 177-184.

Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation. 2004 Mar 30;109(12 Suppl 1):I4-8. Review

Book chapters and review articles

Anderson B, McKiernan JM. Chapter 80, Urethral Cancer. In Campbell Walsh Wein Urology. 2019.

Kurtzman JT, Anderson CB. Is bipolar transurethral bladder tumor resection better? AUA News. January 2019; 24(1).

Sebesta EM, Anderson CB. The Surgical Management of Prostate Cancer. Semin Oncol. Epub Feb 13, 2018.

Anderson CB, DeCastro GJ. Genetic signatures on radical prostatectomy specimens: clinical implications. Transl Cancer Res. 2018; 7 (6): S704-S710.

Anderson CB, McKiernan JM. Surgical complications of urinary diversion. Urol Clin North Amer. 2018. Feb; 45 (1): 79-90.

Anderson CB, McKiernan JM. Complications of radical cystectomy. In Taneja SS, Shah O (Eds.), Complications of Urologic Surgery. 2016

Anderson CB. Voiding function in women with orthotopic neobladders. Current bladder dysfunction reports. 2015; 10: 411-418.

Anderson CB, Musser J, Sfakianos J, Herr HW. Bladder tumors: Association with Upper Tract Neoplasms. In Grasso M, Bagley D (Eds.), Textbook of upper urinary tract urothelial carcinoma. Springer, Switzerland 2015.

Anderson CB, Penson DF, Barocas DA. (2014). Quality of life measures. In Konety BD and Chang SS (Eds.), Management of Bladder Cancer. Springer, New York 2014.

Anderson CB, Cookson MS, Chang SS. (2014). Principles of bladder cancer surgery. In Castle EP and Pruthi R (Eds.) Robotic Surgery of the Bladder. Springer Science + Business Media, New York 2014.

Anderson CB, Helfand BT, McVary KT: Clinical markers of benign prostatic hyperplasia (BPH) progression. Weill Medical College of Cornell University Reports on Men’s Urologic Health. 2007; 2 (2).

Guidelines

Anderson CB, McKiernan JM. Societe Internationale d’Urolgie - International Consultation on Urologic Diseases (SIU-ICUD) Non-muscle invasive bladder cancer guidelines, 2017.